Loading
In bowel cancers that start on the left and have normal RAS and BRAF genes, adding an EGFR antibody to chemotherapy gives the longest survival seen in first-line trials.
PARADIGM: OS 37.9 months with panitumumab + mFOLFOX6 in left-sided RAS wild-type disease. FIRE-3 and CALGB 80405 subgroups agree. Right-sided or RAS/BRAF-mutant tumours should get bevacizumab instead. Anti-EGFR rechallenge after a chemotherapy-free interval, guided by ctDNA showing RAS/EGFR clones have receded (CHRONOS), is an emerging strategy.
Shares PARADIGM, CRYSTAL & FIRE-3, Sidedness (left vs right colon), FOLFIRI (5-FU, leucovorin, irinotecan).
Shares PARADIGM, CRYSTAL & FIRE-3, Sidedness (left vs right colon), Panitumumab.
Shares Panitumumab, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin), Colorectal cancer.
Shares PARADIGM, Sidedness (left vs right colon), Panitumumab, FOLFIRI (5-FU, leucovorin, irinotecan).
Shares CRYSTAL & FIRE-3, Sidedness (left vs right colon), FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab.
Shares PARADIGM, CRYSTAL & FIRE-3, Cetuximab, FOLFOX (5-FU, leucovorin, oxaliplatin).
Shares CRYSTAL & FIRE-3, Sidedness (left vs right colon), FOLFIRI (5-FU, leucovorin, irinotecan), Cetuximab.
Shares Sidedness (left vs right colon), Panitumumab, Cetuximab, Colorectal cancer.